Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly  Settings
ACST [NASD]
Acasti Pharma Inc.
Healthcare | Biotechnology | Canada
financial highlights | statements
Index- P/E- EPS (ttm)-38.78 Insider Own79.43% Shs Outstand9.24M Perf Week3.17%
Market Cap24.02M Forward P/E- EPS next Y- Insider Trans- Shs Float1.90M Perf Month17.12%
Income-2.48M PEG- EPS next Q- Inst Own- Short Float2.85% Perf Quarter3.17%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Ratio1.33 Perf Half Y30.65%
Book/sh0.00 P/B- EPS next Y- ROA- Target Price- Perf Year8.33%
Cash/sh0.00 P/C- EPS next 5Y- ROE- 52W Range1.61 - 3.99 Perf YTD20.93%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-34.84% Beta0.04
Dividend %- Quick Ratio0.00 Sales past 5Y- Gross Margin- 52W Low61.49% ATR0.10
Employees1500 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)66.88 Volatility3.36% 3.56%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.11 Prev Close2.60
ShortableYes LT Debt/Eq- Earnings- Payout0.00% Avg Volume40.89K Price2.60
Recom- SMA206.80% SMA5012.04% SMA20013.71% Volume4,400 Change0.00%
15-Apr-13 08:00AM  The U.S. International Trade Commission (ITC) Votes to Institute Patent Infringements Investigation Based on Neptune & Acasti Complaint GlobeNewswire
03-Apr-13 03:58AM  Krill Oil's Omega-3s And CaPre: Brought To You By Acasti at Seeking Alpha
26-Mar-13 11:36AM  3 Speculative Healthcare Companies With High Levels Of Insider Ownership - Part III at Seeking Alpha
19-Mar-13 08:01AM  InPlay: Acasti Pharma presents preliminary data moving forward with clinical strategy; CaPre achieved a clinically important and statistically significant triglyceride reduction of up to 23% as compared to standard of care, after only a 4-w Briefing.com -11.67%
08:00AM  Acasti Pharma Presents Preliminary Data Moving Forward With Clinical Strategy GlobeNewswire
14-Mar-13 08:00AM  Neptune to Present at the Annual ROTH Conference GlobeNewswire +5.73%
27-Feb-13 12:59AM  Amarin: The More You Know The Fishier It Gets at Seeking Alpha
19-Feb-13 07:19AM  3 Speculative Healthcare Companies With Very High Insider Ownerships at Seeking Alpha
31-Jan-13 08:00AM  Neptune Responds to Aker BioMarine's Attempt to Shift the Focus From Neptune's Major ITC Filing GlobeNewswire
30-Jan-13 08:00AM  Neptune Files ITC Complaint Against Competitors Aker, Enzymotec, Rimfrost, Olympic and Others GlobeNewswire
29-Jan-13 06:29PM  Speculative Quasi-Biotech Neptune Off To A Strong Start In 2013 at Seeking Alpha -5.66%
24-Jan-13 08:00AM  Neptune Obtains Allowance of Patent Specific to Krill Oil and Announces Management Reorganization GlobeNewswire +5.69%
18-Jan-13 12:37PM  Anything For A Buck: Jim Letourneau Looks To Canadian Biotech For Opportunity at Seeking Alpha
15-Jan-13 08:00AM  Acasti Pharma Reports Its Third Quarter Results GlobeNewswire
Acasti Pharma Inc. engages in the research, development, and commercialization of active pharmaceutical ingredients to treat cardiometabolic disorders. It is developing bioactive ingredients of proprietary novel omega-3 phospholipids through the pharmaceutical development pathway, which includes prescription medical foods, over-the-counter products (OTC), and prescription drugs. The company's lead prescription drug candidate, CaPre that is in Phase II clinical trial for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia, a condition which is characterized by abnormally high levels of triglycerides. Its products also include Onemia, an omega-3 phospholipid concentrate and medical food for chronic cardiometabolic disorders. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies and Bioressources Inc.
open in yahoo | open in reuters | open in google